TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21950578
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 400 mg/day
Study: 19679275
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for FCD type II
Study: 19679275
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for FCD type II
Study: 9043731
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate (12.5, 25, 50, or 100 mg)
Study: 7911057
Drug: Bunazosin 3
Normalized name: bunazosin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin 3 mg
Study: 7911057
Drug: Bunazosin 6
Normalized name: bunazosin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin 6 mg
Study: 7911057
Drug: Bunazosin 12
Normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin 12 mg
Study: 7911057
Drug: Bunazosin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin (all doses)
Study: 3328105
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of Prednisone (3960 mg over 54 days, initial dose 200 mg per day)
Study: 3328105
Drug: Medium doses
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium doses of Prednisone (initial dose 60 mg)
Study: 24462581
Drug: Disulfiram 250mg
Normalized name: DISULFIRAM 250MG TAB
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 250mg daily
Study: 20005081
Drug: Selective serotonin-reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin-reuptake inhibitors (SSRIs) for 52 weeks
Study: 15354980
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin (250 IU/h, adjusted in 125 IU/h steps)
Study: 15354980
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin
Study: 7918131
Drug: Acadesine 6
Normalized name: acadesine
DrugBank: Acadesine (DB04944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine 6 mg/kg
Study: 7918131
Drug: Acadesine 12
Normalized name: acadesine
DrugBank: Acadesine (DB04944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine 12 mg/kg
Study: 7918131
Drug: Acadesine 24
Normalized name: acadesine
DrugBank: Acadesine (DB04944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine 24 mg/kg
Study: 7918131
Drug: Acadesine 48
Normalized name: acadesine
DrugBank: Acadesine (DB04944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine 48 mg/kg
Study: 2843201
Drug: Enalapril (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (all doses)
Study: 27749754
Drug: OTO‐104 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTO‐104 (12 mg dexamethasone)
Study: 21227010
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg active TA(1)
Study: 21227010
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg recombinant TA(1)
Study: 21227010
Drug: 3.2 mg
Normalized name: menthol 3.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg recombinant TA(1)
Study: 22283559
Drug: Paroxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine monotherapy
Study: 19108666
Drug: Combination paroxetine-divalproex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination paroxetine-divalproex sodium therapy
Study: 16757447
Drug: Cognitive-behavioral body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral body image therapy
Study: 15291906
Drug: Anti-IgE monotherapy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IgE monotherapy
Study: 15291906
Drug: SIT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT and anti-IgE combined treatment
Study: 15291906
Drug: SIT grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT grass pollen monotherapy
Study: 11211468
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (transmyocardial revascularization and percutaneous myocardial revascularization)
Study: 2908307
Drug: Carvedilol 100
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol 100 mg
Study: 23601463
Drug: Calf blood
Normalized name: deproteinized calf blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf blood extract gel
Study: 21601979
Drug: N-Palmitoylethanolamine-transpolydatin 400
Normalized name: N-palmitoylethanolamine
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Palmitoylethanolamine-transpolydatin 400 mg + 40 mg twice a day for 3 months
Study: 21601979
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice a day for 7 consecutive days
Study: 11030277
Drug: Control (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sodium cromoglycate and beta2-agonist)
Study: 8382588
Drug: dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: dopamine infusion
Study: 3730525
Drug: Spironolactone with
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone with modified extent and rate of absorption
Study: 3730525
Drug: Statistical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical analysis using two-way MANOVA of statistical moments of urinary excretion profiles of canrenone
Study: 26068325
Drug: Maturational training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maturational training group (MG)
Study: 24927164
Drug: Non-flowable topical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-flowable topical hemostats (SURGICEL Nu-Knit, Ethicon-Johnson & Johnson; GELFOAM, Pfizer)
Study: 15339769
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg ethinyl estradiol oral contraceptive pill
Study: 9581698
Drug: Ribavirin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (up to 1.2 g daily for 24 weeks)
Study: 3182481
Drug: Inhaled codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled codeine (50 mg)
Study: 3182481
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine (10 mg)
Study: 3182481
Drug: Oral codeine
Normalized name: codeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral codeine (60 mg)
Study: 3182481
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.15 mg/kg)
Study: 23631513
Drug: CO2 fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 fractional laser therapy
Study: 19289711
Drug: Budesonide respule
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide respule therapy
Study: 15296684
Drug: Waiting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting treatment group
Study: 10537964
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 to 20 mg/day (n = 551)
Study: 10537964
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 to 20 mg/day (n = 266)
Study: 12949850
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 to 20 mg/day
Study: 10474283
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 to 20 mg/day
Study: 31857300
Drug: Standard-oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-oxygen therapy
Study: 29157898
Drug: Bioinductive collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioinductive collagen implant
Study: 12349893
Drug: Extended-duration low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-duration low-molecular-weight heparin therapy
Study: 24030613
Drug: Psychodynamic supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic supportive therapy
Study: 19939653
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester spread (2 g/day)
Study: 19880936
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care intervention consisting of behaviour change counselling, motivational enhancement therapy, and referral to a community alcohol treatment agency.
Study: 16800138
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (5 cc of 1% mepivacaine solution)
Study: 8449075
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (1-2 L/min) for 10 min
Study: 30059188
Drug: Curcumin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (300 mg) twice daily
Study: 30059188
Drug: Lycopene (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (8 mg) twice daily
Study: 29078970
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus gabapentin (300 mg/d)
Study: 29078970
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg/d) alone
Study: 26179187
Drug: Dulaglutide (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (0.75 mg)
Study: 21717138
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) 100 mg immediate-release capsules
Study: 14630560
Drug: Intracoronary beta-radiation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary beta-radiation therapy (9, 12, 15 or 18 Gy at 1 mm tissue depth)
Study: 14630560
Drug: Intracoronary beta-radiation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary beta-radiation therapy without geographical miss (non-GM)
Study: 1451721
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clomipramine b.d. during active therapy
Study: 1451721
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment during the initial week
Study: 26406193
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (ManT)
Study: 26412456
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m² every 3 weeks)
Study: 18317067
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with carboplatin (AUC 5), irinotecan (100 mg/m²), and paclitaxel (175 mg/m²) followed by concurrent chemotherapy with carboplatin (AUC 2) and paclitaxel (45 mg/m² weekly) and gefitinib (250 mg daily) with 3-dimensional TCRT to 74 Gy
Study: 18317067
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and gefitinib concurrent with 3-dimensional TCRT
Study: 16956824
Drug: Deferoxamine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine monotherapy
Study: 9202948
Drug: TTFD (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFD (1 g.day‐1 for 4 days)
Study: 25068497
Drug: PCV7‐TT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7‐TT vaccine
Study: 25068497
Drug: Synflorix (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synflorix (control vaccine)
Study: 22332211
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections plus prompt laser
Study: 22332211
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injections plus prompt laser
Study: 22332211
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injections plus deferred laser
Study: 22332211
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide injections plus prompt laser
Study: 22332211
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections plus prompt laser (for participants with 2 study eyes)
Study: 18508948
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg oral dose of deferasirox tablets
Study: 18508948
Drug: 130 mg
Normalized name: pectin 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 mg intravenous infusion of deferasirox
Study: 16001345
Drug: Ultrasonic contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic contrast agent SHU 508A
Study: 12492738
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (group 4 treatment) for duodenal ulcer patients
Study: 12492738
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 treatment
Study: 8723453
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg dose, orally and intravenously)
Study: 1900148
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with mitomycin C (MMC), 20 mg/m2 administered intravenously once every 6 weeks for four consecutive cycles
Study: 1900148
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving no further treatment after surgery
Study: 6394640
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of oestradiol percutaneously
Study: 6394640
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of oestradiol orally
Study: 27302510
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (CR)
Study: 1358483
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (discontinued treatment when serum TSH level and TBII activity normalized)
Study: 20589566
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fluoxetine and CBT
Study: 15818102
Drug: Omeprazole suspension
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole suspension (40 mg doses on day 1, then 40 mg daily for up to 14 days)
Study: 15818102
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg bolus and 50 mg/hr for up to 14 days)
Study: 12201080
Drug: BDP Modulite
Normalized name: Modulis
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP Modulite (1000 micrograms twice-daily)
Study: 8758093
Drug: AmBisome 2mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 2mg/kg on days 1, 2, 3, 4, 5, 6, and 10 (total dose 14 mg/kg)
Study: 8758093
Drug: AmBisome 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 2 mg/kg on days 1, 2, 3, 4, and 10 (total dose 10 mg/kg)
Study: 8758093
Drug: AmBisome 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 2 mg/kg on days 1, 5 and 10 (total dose 6 mg/kg)
Study: 25050491
Drug: Cyclosporine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (2.5 mg/kg)
Study: 30882527
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy (including occupational therapy)
Study: 22361318
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant 0.7 mg (Ozurdex)
Study: 20554790
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1500 mg Ca/d)
Study: 21864399
Drug: Comprehensive Geriatric
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Geriatric Assessment intervention by a specialist physician in geriatric medicine
Study: 16060203
Drug: Homeopathic medicine
Normalized name: Homeopathic medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicine (individually prescribed) for 6 weeks
Study: 16060203
Drug: Homeopathic medicine
Normalized name: Homeopathic medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicine (individually prescribed) during open follow-up
Study: 9832293
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg x ml(‐1) oxymetazoline (Group B)
Study: 9832293
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x ml(‐1) oxymetazoline (Group C)
Study: 8018452
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lofepramine (70 mg once daily)
Study: 29235884
Drug: Vortioxetine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10-20 mg/day) with UPSA score change ≥9
Study: 29235884
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg/day) with UPSA score change ≥9
Study: 16782312
Drug: Antidepressants (95%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (95% were selective serotonin or norepinephrine reuptake inhibitors, or second-generation antidepressants)
Study: 16782312
Drug: Antidepressants (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (with concurrent mood stabilizer)
Study: 18342952
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care without antidepressants
Study: 14504184
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily for 8 weeks
Study: 14504184
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily for 8 weeks
Study: 8805928
Drug: Cisplatin in
Normalized name: cisplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin in combination with teniposide and vincristine
Study: 8805928
Drug: Carboplatin in
Normalized name: Carboplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin in combination with teniposide and vincristine
Study: 8805928
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with teniposide plus cisplatin or carboplatin
Study: 8805928
Drug: Alternating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating treatment with block A, B and C (arm III)
Study: 6385890
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg every 6 hours)
Study: 24662864
Drug: Balanced electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced electrolyte solution (BES) plus low FFP/RBC resuscitation (Group A)
Study: 23087138
Drug: Buprenorphine (BNP)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine (BNP) 0.000025 g x kg(‐2) administered by patient‐controlled intravenous analgesia (PCIA)
Study: 23087138
Drug: Morphine 0.00075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.00075 g x kg(‐2)
Study: 23087138
Drug: Morphine 0.0011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.0011 g x kg(‐2)
Study: 18843002
Drug: BR-DIM 100
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR-DIM 100 mg
Study: 18843002
Drug: BR-DIM 200
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR-DIM 200 mg
Study: 18843002
Drug: BR-DIM 300
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR-DIM 300 mg
Study: 12036805
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil with 150 mg phytosterols
Study: 12036805
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil with 300 mg phytosterols
Study: 8569975
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of alkaline salts of calcium
Study: 8569975
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate calcium concentrations (1.25-1.00 mmol/l)
Study: 8569975
Drug: Nonhypercalcemic hyperphosphatemic
Normalized name: 1-36 human humoral hypercalcemic factor
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhypercalcemic hyperphosphatemic vitamin D3 derivatives in combination with oral calcium
Study: 1697390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nisoldipine and propranolol
Study: 100331
Drug: Fibroblast interferon
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibroblast interferon preparations for 3 months
Study: 28383400
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily (except on dialysis days)
Study: 28383400
Drug: Standard non-RAAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard non-RAAS antihypertensive agents
Study: 9034263
Drug: Gentamicin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (loading dose administered)
Study: 8094392
Drug: Dexamethasone (DEX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (DEX; 8 mg, orally)
Study: 8094392
Drug: Propranolol (PRO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (PRO; 40 mg, orally) after DEX
Study: 8094392
Drug: Clonidine (CLO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (CLO; 0.300 mg, orally) after DEX
Study: 8094392
Drug: Pyridostigmine (PD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD; 120 mg, orally) after DEX
Study: 3298088
Drug: Liquid carbohydrate-rich
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid carbohydrate-rich feeding (L)